Takeda Pharmaceutical (TAK) Net Cash Flow (2018 - 2026)

Takeda Pharmaceutical's Net Cash Flow history runs 9 years deep, the most recent figure standing at $711.5 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 209.3% year-over-year to $711.5 million in Q1 2026; TTM through Mar 2026 was $2.3 billion, a 629.18% increase from a year earlier, with the FY2026 full-year figure at $2.3 billion, up 674.5% from the prior year.
• Net Cash Flow climbed to $711.5 million in Q1 2026 per TAK's latest filing, from -$318.4 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $2.2 billion in Q3 2025 and bottomed at -$2.6 billion in Q4 2024.
• The 5-year median for Net Cash Flow is -$179.8 million (2023), against an average of -$36.1 million.
• Biggest YoY gain for Net Cash Flow was 4081.95% in 2024; the steepest drop was 1318.55% in 2024.
• Year by year, Net Cash Flow stood at -$732.0 million in 2022, then soared by 75.44% to -$179.8 million in 2023, then tumbled by 1318.55% to -$2.6 billion in 2024, then jumped by 87.52% to -$318.4 million in 2025, then jumped by 323.5% to $711.5 million in 2026.
• Per Business Quant, the three latest TAK Net Cash Flow figures stand at $711.5 million (Q1 2026), -$318.4 million (Q4 2025), and $2.2 billion (Q3 2025).